Evaluation of Oxalate Osteopathy Secondary to Hyperoxaluria With 18F-FDG PET/CT and 99mTc-HMDP Bone Scan.

Date publication

février 2019

Journal

Clinical nuclear medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Dr SOMME François

Tous les auteurs :
Somme F, Blondet C, Matuszak J, Heimburger C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30516684

Résumé

We report a case of a 69-year-old woman with primary hyperoxaluria type I, who developed a severe hypercalcemia despite controlled secondary hyperparathyroidism. Bone scintigraphy showed diffuse increased uptake in axial and peripheral skeleton. F-FDG PET/CT showed countless striking hypermetabolic foci, interesting 2 types of lesions (joint calcifications and periosteal resorptions). Bone biopsy demonstrated inflammatory changes around many calcium oxalate crystals; hypercalcemia was then related to oxalate osteopathy. Immunotherapy with denosumab was thus initiated. Eighteen months later, a second PET/CT showed decreased F-FDG uptake, reflecting treatment efficacy on inflammatory reaction secondary to calcium oxalosis skeletal deposits.

Mots clés

Aged, Female, Fluorodeoxyglucose F18, Humans, Hyperoxaluria, Primary, complications, Positron Emission Tomography Computed Tomography, Technetium Tc 99m Medronate, analogs & derivatives

Référence

Clin Nucl Med. 2019 02;44(2):123-124